Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by aldo451on Nov 01, 2017 12:04am
235 Views
Post# 26885894

RE:RE:RE:RE:RE:RE:Cant say I like the price.

RE:RE:RE:RE:RE:RE:Cant say I like the price.Hi Balain,
 
great post as always! I am a shareholder since 2005 or 12 long years! and like you, and other longs, I’m sure, feel the same way about how things do not appear to be lining up as anticipated.
 
Speaking of which, here is an example (one of many) where things do not materialize as originally announced by PLI.

I wrote Fred back on August 25 regarding the SRAM deal. 

News release
 
March 30, 2017
 
SRAM, a leading investment group in healthcare in China, will provide $23 million in 2017, $13 million upfront and $10 million expected in H2 2017, to secure an initial 17% ownership of Prometic ChinaCo, with a right to increase it up to 25% with a further $10 million investment related to milestones expected in 
 
August 14, 2017
 
SRAM’s initial funding of $33 million is earmarked for the clinical development of the Products, currently on-going outside China. Of the $33 million, $23 million is receivable in the second half of 2017 
 
Fred, two things I would like answered;
 
1.      What happened to $13 million upfront?
2.      We are in the 2nd half. What is the date this payment is expected?
 
Fred’s reply, Sept 7: These should appear in the Q3 financial statements to be disclosed mid-November
  
I comfort myself by saying that it is all moving along as planned, it’s just taking longer than expected.

I also agree that there seems to be no apparent evidence that institutional investment firms are promoting/buying the stock! For example, what is Cantor Fitzgerald doing with the shares they acquired in June?  As a matter of fact, I entered Prometic in their search engine and nothing came up! I guess they are holding out for the opportune time, possibly once approval is granted and/or the upturn begins.
 
Anyhow, very frustrating to see my money just stagnating because I do not have the balls to risk playing the stock.
 
Onwards & Upwards as PL would say!
 
Cheers
Aldo  
 
Bullboard Posts